Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2022-08-29 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Dr. Francesco De Meo), their position ('Member of the managing body'), the nature of the transaction ('Disposal'), the financial instrument (Share), and the price/volume details. This content directly matches the definition for Director's Dealing.
2022-08-29 English
Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
Board/Management Information Classification · 100% confidence The document is a short announcement dated August 19, 2022, titled 'Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius'. It explicitly details the succession plan for the Chief Executive Officer role, including appointment dates and background information on the incoming and outgoing executives. This content directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-08-19 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: Fresenius SE & Co. KGaA english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. It details the name of an individual (Stephan Sturm), their position ('Member of the managing body'), and records specific transactions (Acquisition) involving company shares with prices and volumes. This content perfectly matches the definition for Director's Dealing.
2022-08-05 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Stephan Sturm), their position ('Member of the managing body'), and the nature, price, and volume of the transaction (Acquisition of shares). This content directly matches the definition for Director's Dealing.
2022-08-05 English
Half-yearly financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT' and covers the 'H1 2022' period. It contains detailed financial statements, including the consolidated statement of income, cash flows, and financial position, as well as an interim management report. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-04 German
Conference Call Q2 Results 2022, Fresenius
Investor Presentation Classification · 98% confidence The document text explicitly states it is a "Conference Call | Q2/22 Preliminary Results" presentation from July 28, 2022. It contains key messages, guidance updates, detailed segment performance tables (Kabi, Helios, Vamed) for Q2/22 and H1/22, and an agenda for the call. This structure—a presentation summarizing recent financial performance, often accompanied by a call—is characteristic of an Earnings Release (ER) or a presentation that accompanies one. Since it provides preliminary results and guidance adjustments, it functions as the primary communication of recent earnings, fitting the definition of an Earnings Release (ER). It is not a full, comprehensive report (10-K or IR), nor is it just a transcript (CT) or a simple announcement of a report (RPA).
2022-07-28 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.